A Cannatà, G Anastasia, V De Marzo, O Caspi, D Bromage, I Porto, G Savarese, T McDonagh, Z L Cox, P Ameri
{"title":"急性心力衰竭的利尿策略：随机临床试验的系统回顾和网络荟萃分析。","authors":"A Cannatà, G Anastasia, V De Marzo, O Caspi, D Bromage, I Porto, G Savarese, T McDonagh, Z L Cox, P Ameri","doi":"10.1093/ehjcvp/pvaf067","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Several diuretic strategies, including furosemide iv boluses (FB) or continuous infusion (FC), are used in acute heart failure (AHF).</p><p><strong>Methods and results: </strong>We systematically searched phase 3 randomized clinical trials (RCTs) evaluating diuretic regimens in admitted AHF patients within 48 hours and irrespective of clinical stabilization. We calculated the odds ratio (OR) of FC or FB plus another diuretic (sequential nephron blockade, SNB) compared to FB alone on 24-hour weight loss (WL) and worsening renal function (WRF), with a random-effects model with inverse variance weighting. Urine output, hypokalaemia, hyponatremia, and all-cause mortality/rehospitalization were secondary endpoints.In 25 selected RCTs (7,149 patients, mean age 68.9±8.7 years, mean LVEF 38.2±10.7%), FC (OR 1.55 [95% confidence interval 1.39-1.63], FB plus tolvaptan (OR 1.57 [1.39-1.77]), FB plus SGLT2i (OR 1.23 [1.06-1.42]), and FB plus thiazide (OR 1.63 [1.37-1.94]) were associated with greater WL than FB. FB plus SGLT2i (OR 1.52 [1.19-1.94]) and FB plus acetazolamide (OR 1.81 [1.31-2.49]) were associated with WRF. FB plus thiazide was associated with both WRF (OR 1.78 [1.43-2.21]) and hypokalaemia (OR 1.69 [1.32-2.16]). Results were consistent in sensitivity analyses considering urine output, RCTs protocol-established furosemide doses, or daily furosemide dose. Congestion/decongestion scores and clinical outcomes were reported in around 50% of RCTs. In an underpowered exploratory analysis, mortality/rehospitalization was non-significantly lower with SGLT2i (OR 0.45 [0.19-1.07]).</p><p><strong>Conclusions: </strong>FC and SNB improve surrogates of response to FB in AHF. SNB is also connoted by WRF and may induce hypokalaemia. The endpoints of diuretic RCTs should be revised and harmonized.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials.\",\"authors\":\"A Cannatà, G Anastasia, V De Marzo, O Caspi, D Bromage, I Porto, G Savarese, T McDonagh, Z L Cox, P Ameri\",\"doi\":\"10.1093/ehjcvp/pvaf067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Several diuretic strategies, including furosemide iv boluses (FB) or continuous infusion (FC), are used in acute heart failure (AHF).</p><p><strong>Methods and results: </strong>We systematically searched phase 3 randomized clinical trials (RCTs) evaluating diuretic regimens in admitted AHF patients within 48 hours and irrespective of clinical stabilization. We calculated the odds ratio (OR) of FC or FB plus another diuretic (sequential nephron blockade, SNB) compared to FB alone on 24-hour weight loss (WL) and worsening renal function (WRF), with a random-effects model with inverse variance weighting. Urine output, hypokalaemia, hyponatremia, and all-cause mortality/rehospitalization were secondary endpoints.In 25 selected RCTs (7,149 patients, mean age 68.9±8.7 years, mean LVEF 38.2±10.7%), FC (OR 1.55 [95% confidence interval 1.39-1.63], FB plus tolvaptan (OR 1.57 [1.39-1.77]), FB plus SGLT2i (OR 1.23 [1.06-1.42]), and FB plus thiazide (OR 1.63 [1.37-1.94]) were associated with greater WL than FB. FB plus SGLT2i (OR 1.52 [1.19-1.94]) and FB plus acetazolamide (OR 1.81 [1.31-2.49]) were associated with WRF. FB plus thiazide was associated with both WRF (OR 1.78 [1.43-2.21]) and hypokalaemia (OR 1.69 [1.32-2.16]). Results were consistent in sensitivity analyses considering urine output, RCTs protocol-established furosemide doses, or daily furosemide dose. Congestion/decongestion scores and clinical outcomes were reported in around 50% of RCTs. In an underpowered exploratory analysis, mortality/rehospitalization was non-significantly lower with SGLT2i (OR 0.45 [0.19-1.07]).</p><p><strong>Conclusions: </strong>FC and SNB improve surrogates of response to FB in AHF. SNB is also connoted by WRF and may induce hypokalaemia. The endpoints of diuretic RCTs should be revised and harmonized.</p>\",\"PeriodicalId\":11982,\"journal\":{\"name\":\"European Heart Journal - Cardiovascular Pharmacotherapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal - Cardiovascular Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjcvp/pvaf067\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvaf067","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials.
Aims: Several diuretic strategies, including furosemide iv boluses (FB) or continuous infusion (FC), are used in acute heart failure (AHF).
Methods and results: We systematically searched phase 3 randomized clinical trials (RCTs) evaluating diuretic regimens in admitted AHF patients within 48 hours and irrespective of clinical stabilization. We calculated the odds ratio (OR) of FC or FB plus another diuretic (sequential nephron blockade, SNB) compared to FB alone on 24-hour weight loss (WL) and worsening renal function (WRF), with a random-effects model with inverse variance weighting. Urine output, hypokalaemia, hyponatremia, and all-cause mortality/rehospitalization were secondary endpoints.In 25 selected RCTs (7,149 patients, mean age 68.9±8.7 years, mean LVEF 38.2±10.7%), FC (OR 1.55 [95% confidence interval 1.39-1.63], FB plus tolvaptan (OR 1.57 [1.39-1.77]), FB plus SGLT2i (OR 1.23 [1.06-1.42]), and FB plus thiazide (OR 1.63 [1.37-1.94]) were associated with greater WL than FB. FB plus SGLT2i (OR 1.52 [1.19-1.94]) and FB plus acetazolamide (OR 1.81 [1.31-2.49]) were associated with WRF. FB plus thiazide was associated with both WRF (OR 1.78 [1.43-2.21]) and hypokalaemia (OR 1.69 [1.32-2.16]). Results were consistent in sensitivity analyses considering urine output, RCTs protocol-established furosemide doses, or daily furosemide dose. Congestion/decongestion scores and clinical outcomes were reported in around 50% of RCTs. In an underpowered exploratory analysis, mortality/rehospitalization was non-significantly lower with SGLT2i (OR 0.45 [0.19-1.07]).
Conclusions: FC and SNB improve surrogates of response to FB in AHF. SNB is also connoted by WRF and may induce hypokalaemia. The endpoints of diuretic RCTs should be revised and harmonized.
期刊介绍：
The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is an international, peer-reviewed journal published in English, specifically dedicated to clinical cardiovascular pharmacology. EHJ-CVP publishes original articles focusing on clinical research involving both new and established drugs and methods, along with meta-analyses and topical reviews. The journal's primary aim is to enhance the pharmacological treatment of patients with cardiovascular disease by interpreting and integrating new scientific developments in this field.
While the emphasis is on clinical topics, EHJ-CVP also considers basic research articles from fields such as physiology and molecular biology that contribute to the understanding of cardiovascular drug therapy. These may include articles related to new drug development and evaluation, the physiological and pharmacological basis of drug action, metabolism, drug interactions, and side effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
